ENG_VER 12.03.2026 BEŞERI TIBBI ÜRÜNLERIN FIYATLANDIRILMASINA DAIR KARAR (002)

THURSDAY,March12,2026 OfficialGazette Issue:33194 PRESIDENTIALDECREE DecreeNumber:11031
PursuanttothesecondparagraphofArticle352ofthePresidentialDecreeNo.1,theattached "DecreeonthePricingofMedicinalProductsforHumanUse"hasbeenputintoeffect. March11,2026 RecepTayyipERDOĞAN PRESIDENT

DECREEONTHEPRICINGOFMEDICINALPRODUCTSFORHUMANUSE Purposeandbasis
ARTICLE1-(1)PursuanttotheLawonPharmaceuticalandMedicalPreparationsnumbered1262 anddated14/5/1928,theFundamentalLawonHealthServicesnumbered3359anddated7/5/1987,andthe PresidentialDecreeontheOrganizationofthePresidencynumbered1anddated10/7/2018,theMinistryof Healthshalldeterminethemaximumpricesbytakingthenecessarymeasurestoensurethatmedicinal productsforhumanusereachtheconsumerunderappropriateconditions.Thepricesrequestedby marketingauthorizationholdersorapplicantsinaccordancewiththisDecreeshallbeapprovedbythe MinistryofHealthandannouncedwiththeeffectivedate. Determinationofprices
ARTICLE2-(1)Aminimumof5andamaximumof10countriesamongthemembersofthe EuropeanUnionshallbedesignatedassourcecountriesbytheMinistryofHealthandannouncedthrougha communiqué.Thedesignatedsourcecountriesmaybechanged,providedthattheyareannouncedatleast twomonthsinadvance.Theactualsourcepriceistheex-factoryprice.Thispriceisthelowestex-factory price,excludingdiscounts,ofthesourceproductauthorizedandavailableforsaleinthemarketinthe designatedcountries.However,ifthecountrieswherethebatchoftherelevantproductisreleasedor imported areoutsidethesourcecountriesandthereisanex-factorypricedeterminedbelowthepricesofthe sourcecountriesinsuchcountries,thepriceinthecountrywiththelowerex-factorypriceshallbeaccepted astheactualsourceprice.
(2)TheactualsourcepriceshallbeinEuro,andcompaniesshallberesponsiblefortrackingand declaringtheactualsourcepricesfortherelevantproductstotheMinistryofHealth.Nationalor international databasesmaybeusedforactualsourcepricetracking.Whendeemednecessary,theMinistry ofHealthmaychecktheactualsourcepricesdeclaredbyusingnationalorinternationaldatabasesand/or officialchannels.Ifthereisadifferencebetweenthedeclaredpricesandthepricesdeterminedasaresultof thecontrol,theMinistryofHealthshallapplythepricesithasdetermined.
(3)Thevalueof1EuroinTurkishLiratobeusedinthepricingofmedicinalproductsforhuman useshallbedeterminedbymultiplyingtheadjustmentcoefficientsetas65%oftheannualaverageEuro value,tobecalculatedbasedonthedailyEuroexchangesalesratesoftheCentralBankoftheRepublicof Turkey,whichareindicativeofthepreviousyear'sOfficialGazette.ThePriceEvaluationCommissionshall convenewithinthefirst45daysofeachyearandannouncethevalueof1Eurotobeusedinthepricingof medicinalproductsforhumanuseinaccordancewiththeabove-mentionedprocedures.
(4)Inthecaseofcountrieswithdifferentcurrencies,theeuroequivalentforcurrenciesforwhich theCentralBankoftheRepublicofTurkeyhasofficiallyannouncedtheforeignexchangesellingrate,the foreignexchangesellingrateonFebruary13,2009shallbeused,andforcurrenciesforwhichtheCentral BankoftheRepublicofTurkeyhasnotofficiallyannouncedtheforeignexchangesellingrate,the conversion rateonthedatementionedonthewebsiteoftherelevantcountry'sofficialrepresentativeoffice inTurkey,oronthewebsiteofthatcountry'scentralbank,oronthewebsiteoftheEuropeanCentralBank shallbeused. (5)ThesourcepriceisthepriceinEurocalculatedbyproratingtheactualsourceprice.The companysellingpriceshallbetheTurkishLiraequivalentofthesourcepriceuptotheperiodicEurovalue specifiedinthethirdparagraph.Forproductscurrentlyonsale,withpricesapprovedbytheMinistryof Health,orforwhichapriceapplicationhasbeenmadeforthefirsttime,thereferenceproduct'ssourceprice maynotexceedtheactualsourcepriceuntilequivalentproductsareplacedonthemarket,andthesource priceofthereferenceproductforwhichanequivalentproducthasbeenreleasedtothemarketshallbea maximumof60%oftheactualsourcepriceregisteredintheMinistryofHealthdatabase.Theactualsource pricerecordedintheMinistryofHealthdatabaseiscalledthebenchmarksourceprice.

sion published by the Turkish Medicines and Medical Devices Agency (TİTCK), imported from the AIFD Legislation Portal archive. In the event of any discrepancy, the Turkish original text (mevzuat.g

(6)Thesourcepriceofequivalentproductsforwhichthereferenceproductisnotavailablein Turkey shallbe60%ofthebenchmarksourceprice,andallequivalentproductsfromthefirstequivalent productonwardsmaybeassignedapriceofupto60%ofthebenchmarksourcepriceofthereference product.Intheeventthatthereferenceproductisintroducedtothemarketaftertheequivalentproduct alreadyonthemarket,thereferenceproductshallbeassignedasourcepriceofupto60%oftheactual sourcepriceandthereferenceproductshallbetakenasabasisinthepricesofequivalentproducts.
(7)Anydecreaseintheactualsourcepricetooccurafterthepricedeterminedbythe Ministryof Healthwit hthefirstequivalentproductshallnotbereflectedinthesourcepriceuntiltheyfallbelowthe60% limit.Whentheactualsourcepricefallsbelowthe60%threshold,thesourcepricemaybechargedupto 100%ofthenewactualsourceprice.Thisexactprocedureshallalsoapplytotheequivalentproducts.The sourcepriceofequivalentproductsmaynotbehigherthanthesourcepriceofreferenceproducts.
(8)Productsthatfirstappearedontheglobalmarketinanypharmaceuticalformbefore1/1/2000 shallbe consideredtobeprice-protectedproducts.Thesourcepricesofprice-protectedreferenceproducts withacompanysellingpriceaboveTRY92.65maybeatmost80%oftheactualsourceprice.Anydecrease intheactualsourcepricetooccurafterthepricedeterminedbytheMinistryofHealthshallnotbereflected inthesourcepriceuntiltheyfallbelowthe80%limit.Whentheactualsourcepricefallsbelowthe80% threshold,thesourcepricemaybechargedupto100%ofthenewactualsourceprice,andthisexact procedureshallalsoapplytotheequivalentproducts.
(9)Ifthepriceofthereferenceproductwhoseactualsourcepricefallsbelowthe60%limit increasessoastofallbetween60%and100%ofthebenchmarksourceprice,thesourcepricemaynot exceed60%ofthebenchmarksourceprice.Ifthepriceofthereferenceproductwhoseactualsourceprice fallsbelowthe60%limitincreasessoastoexceedthebenchmarksourceprice,thesourcepriceshallbe calculatedtobe60%ofthenewactualsourceprice.Thenewactualsourcepriceshallthenbeusedasthe newbenchmarksourceprice.Thisexactprocedureshallalsoapplytoalltheequivalentproductsofthe ref erenceproducts.Ifthepriceoftheprice-protectedreferenceproductwhoseactualsourcepricefallsbelo w
the80%limitincreasessoastofallbetween80%and100%ofthebenchmarksourceprice,thesourceprice maynotexceed80%oftheoriginalactualsourceprice.Ifthepriceoftheprice-protectedreferenceproduct whoseactualsourcepricefallsbelowthe80%limitincreasessoastoexceedthebenchmarksourceprice, thesourcepriceshallbecalculatedtobe80%ofthenewactualsourceprice.Thenewactualsourceprice shallthenbeusedasthenewbenchmarksourceprice.Thisexactprocedureshallalsoapplytoallthe equivalentproductsoftheprice-protectedreferenceproducts.
(10)The60%valuesmentionedinthefifth,seventhandninthparagraphsshallbeappliedas80%in thefirstyear,75%inthesecondyearand70%inthethirdyearforallequivalentproductswheretheEuro equivalentof60%oftheactualsourcepriceisTRY139.62orabove,startingfromthedateofplacingthe firstequivalentproductonthemarket,providedthatitdoesnotexceedsixmonthsfromthedateof authorization.
(11)Ifthedateofplacingthefirstequivalentproductonthemarketasreferredtointhetenth paragraphexc eedsthedateofmarketingauthorizationbysixmonths,theperiodofapplicationshallstartat theendofthesix-monthperiodfollowingthedateofmarketingauthorization.
(12)Thevalueof75%inthesecondyearmentionedinthetenthparagraphshallbeappliedas80% ifthemar ketshareofmanufacturedequivalentproductsintotalannualconsumptionreaches5%attheend ofthefirstyearaccordingtothedatafromthedrugtrackingsystem.Thevalueof70%inthethirdyearshall beappliedas75%ifthemarketshareofmanufacturedequivalentproductsintotalannualconsumption reaches10%attheendofthesecondyearaccordingtothedatafromthedrugtrackingsystem.
(13)Price-protectedproductswithacompanysellingpriceofTRY92.65orbelow,allmedicines withacompanysellingpriceofTRY48.41orbelow,non-prescriptionmedicines,bloodproducts,foodsfor specialmedicalpurposes,radiopharmaceuticalproducts,enteralnutritionproducts,allergyproducts,or phan products,traditionalherbalmedicinalproducts,biosimilarproducts,hospitalproducts,serums, non-refundablemedicines,medicinessubjecttovalue-basedpricingtobedeterminedbythePrice EvaluationCommission,vaccinesandproductsofcriticalimportanceintermsofpublichealthmaybe

sion published by the Turkish Medicines and Medical Devices Agency (TİTCK), imported from the AIFD Legislation Portal archive. In the event of any discrepancy, the Turkish original text (mevzuat.g

pricedseparatelywithoutbeingboundbytheprovisionsofthisDecree.

Theproceduresandprinciplesregardingthepricingoftheseproductsshallbedeterminedbyacom muniqué tobeissuedbytheMinistryofHealthinconsultationwiththeMinistryofTreasuryandFinance,the DirectorateofStrategyandBudgetandtheDirectorateoftheSocialSecurityInstitution.

(14)ThevaluesofTRY92.65,TRY48.41,TRY139.62referredtointhisArticleshallbeupdated inproportiontothechangeinthevalueoftheEuroasdefinedinthethirdparagraph.

(15)Aftertheproductsincludedintheforeignmedicinalproductlistareauthorizedin Turkey,their actualsourcepricesshallbedeterminedinaccordancewiththeprovisionsofthisDecreeandthe CommuniquéonthePricingofMedicinalProductsforHumanUse.However,thecompanysellingpricesof theproductsmaynotexceedthecurrentexchangerateequivalentofthepriceintheForeignDrugPriceList (Annex4/C)attachedtotheSocialSecurityInstitutionHealthImplementationCommuniqué.

(16)Discountsthatcausetemporarypricechangesinthecountry/countrieswheretheproductis offeredf orsale,specialpracticesregardingproductclassificationandspecialtaxationpracticesshallnotbe takenintoaccountinthecalculationoftheactualsourceprice.Productsthatarenotsoldbyretailinthe cou ntry/countrieswheretheyareofferedforsaleandaremadeavailableonlythroughhospitalsshallnotbe takenintoaccountinthecalculationoftheactualsourcepriceofproductsthataresoldbyretailinTurkey. TheapplicantcompaniesshallsubmitthedocumentscertifyingthisissuetotheTurkishMedicinesand MedicalDevicesAgencytogetherwiththeapplication.

(17)Incaseswherethesourceproductoftheimportedproductsmaynotbedeterminedasperthe sixteenthparagraph,whicharecurrentlyonretailsaleinTurkeyorshalldemandaretailsaleprice,the sellingpriceoftheproducttoawarehouse,whichisnotsoldbyretailinanycountryandisofferedforsale onlythroughthehospitalchannel,shallbetakenintoaccountincalculatingtheactualsourceprice.

(18)Ifthepriceoftheproductisnotavailableinthedesignatedcountriesandinthecountrieswhere itsbatchesarereleasedand/orimported,thepricemaybedeclaredfromothercountriesintheEuropean Unionand,ifnotavailablehere,fromanycountryintheworld.

(19)Manufacturedproductsmaybepricedwithacostcardifthesourceproductmaynotbe identified.

(20)Uponthecommuniquétobeissuedbytheministryofhealth,thepricesofsimilarand/or equivalentproductsmaybeprorated. PriceEvaluationCommission

ARTICLE3-(1)Forthepurposeofevaluatingdrugprices,thePriceEvaluationCommissionshall consistofatotaloffivemembers:onememberfromtheMinistryofHealth,twomembersfromtheMinistry ofTreasuryandFinance,onememberfromtheDirectorateofStrategyandBudget,andonememberfrom theDirectorateofSocialSecurityInstitution,withtheparticipationofrepresentativesatleastatthelevelof generaldirectororauthorizeddepartmentheadunderthecoordinationoftheMinistryofHealth.The Co mmissionshallconveneatleastonceineachcalendaryear.Whennecessary,itconvenesextraordinarily upontheinvitationofanyoftheinstitutionsrepresentedinthecommission.TheCommissionshalltake decisionstoincrease,decreaseorkeepthepricesofmedicinalproductsunchangedortopriceproducts whosepricescannotbedeterminedinaccordancewiththeprovisionsofthisDecree.

(2)PricesofmedicinalproductsmaybeincreasedatratestobedeterminedbythePriceEvaluation Commission.However,non-product-specificgeneralincreasedecisionstakenbythePriceEvaluation CommissionshallalsoapplytootherproductsbytheMinistryofHealthuponrequest.Thesecretariat servicesoftheCommissionshallbecarriedoutbytheMinistryofHealth.

(3)PriortotheincreaseintheEurovalueusedforpricinghumanmedicinalproducts,ifthe product-specificpriceincreasemadebythePriceEvaluationCommission,excludingactualsourceprice changes,exceedstheincreaseintheEurovalue,noadditionalincreaseshallbemadetothepriceofthis product.Iftherateofincreaseintheproduct-specificpriceislessthantherateofincreaseinthevalueofthe Euro,thepriceofthisproductshallbefurtherincreasedbythedifference.However,noadjustmentshallbe madeforincreasesintheEurovalueinproductswhererequestsforcompensationforthecostofraw materialshavebeendeemedappropriatebytheCommission.

(4)ThePriceEvaluationCommissionmayconveneupontheinvitationoftheMinistryofHealthto ensuresustainablehealthservicedelivery andtakeexofficiodecisions.

sion published by the Turkish Medicines and Medical Devices Agency (TİTCK), imported from the AIFD Legislation Portal archive. In the event of any discrepancy, the Turkish original text (mevzuat.g

(5)PursuanttoArticle73oftheSocialInsuranceandGeneralHealthInsuranceLawNo.5510 datedMay31,2006,fordrugssubjecttopurchasesmadeusingalternativereimbursementmodelsandfor non-reimbursabledrugs,ThePriceEvaluationCommissionmaydeterminethesourceand/orsellingprice s
and/orprofitratesofdrugsbydifferentiatingthemorusingdifferentpricingmodels,withoutbeingbound bytheprovisionsofthisDecree. Priceapplications
ARTICLE4-(1)MarketingauthorizationholdersorapplicantsshallapplytotheMinistryofHealth withthePriceDeclarationFormforinitialpriceandactualsourcepricechangerequests.Initialprice applicationsshallbefinalizedwithin90days.Applicantsshallberesponsiblefortheaccuracyofthe docum entssubmitted.Withoutprejudicetotheprovisionsoftheturkishpenalcodedated26/9/2004and numbered5237,thepublicreceivablearisingfromunjustgainsduetoincomplete,misleadingorfalse declarationsshallbecollectedfromthemarketingauthorizationholdersbytheSocialSecurityInstitution andotherrelevantinstitutionsandorganizations. Changesinactualsourceprice
ARTICLE5-(1)Forproductsforwhichactualsourcepricemonitoringisperformed,companies shallbereq uiredtodeclarenotificationsregardingactualsourcepricechangesonceayear.Theprocedures andprinciplesregardingthenotificationshallbedeterminedbycommuniqué.Publicreceivablesarising fromunjustgainsduetofailuretoreportpricereductionslinkedtoactualsourcepriceswithinthespecified timeframeshallbecollectedfrommarketingauthorizationholdersbytheSocialSecurityInstitutionand otherrelevantinstitutionsandorganizations,subjecttotheprovisionsofTurkishPenalCodeNo.5237. Profitrates ARTICLE6-(1)Thewarehouseandpharmacistprofitratestobeappliedwhiledeterminingthe retailsellingpriceoftheproducts,excludingthemedicinesinparagraphfifthofArticle3,shallbeapplied asfollows. OftheCompanySellingPrice; WarehouseProfit(%)PharmacistProfit(%) FortheportionuptoTRY406.76(including TRY406.76) 8 28 FortheportionbetweenTRY406.76andTRY 814.77(includingTRY814.77) 6 18 FortheportionaboveTRY814.77 3 13
(2)Thecompanysellingpricethresholdsbasedonthewarehouseandpharmacistprofitratesapplied whe ndeterminingtheretailpriceofproductsotherthanthemedicinalproductslistedinthefifthparagraph ofArticle3shallbeincreasedinproportiontothechangeintheEurovalue. Pricechanges
ARTICLE7-(1)Thepricesofproductsthatareimportantforpublichealthandwhosepresencein themarketismandatoryandofproductswhosepresenceinthemarketsavespublicmoneymaybe increasedbythedecisionofthePriceEvaluationCommission.
(2)Optionalreductionsinthepricelistshallbeeffective60daysafterthedateofannouncement. However ,iftherelevantcompanyundertakestocoverthepharmacyandwarehousestocklosses,thisperiod shallnotapply.Inaddition,thisperiodshallnotapplytonewproductsaddedtothepricelist,productsfor w hichapriceincreasehasbeengrantedbythePriceEvaluationCommission,priceadjustmentsmadebythe MinistryofHealthandotherchangesnotrelatedtopricechange.

Inthesecases,thepricelistshallbepublishedeveryFriday;ifFridayisapublicholiday,itshallbe publi shedonthepreviousbusinessdayandshallbeeffectiveonthefirstTuesdayfollowing.Incasesthat haveapositiveimpactonpublicfinanceordeemedappropriatebytheMinistryofHealth,the announcementand/oreffectivedatesmaybechanged.
(3)ChangestotheEurovalueusedforthedeterminationofthepricesofmedicinalproductsshall enterintoforce5daysafterthepublicationoftheCommission'sdecisioniftheannouncedEurovalueisan increasecomparedtothepreviousperiodicEurovalue,and45daysafterthepublicationofthe Commission'sdecisioniftheannouncedEurovalueisadecreasecomparedtothepreviousyear. Authorizationtoissuecommuniqués
ARTICLE8-(1)TheMinistryofHealthisauthorizedtoissueacommuniquéonthe implementationofthisDecree. Legislationrepealed
ARTICLE9-(1)DecreeonthePricingofMedicinalProductsforHumanUse,whichwasputinto effectbytheCouncilofMinistersDecreedated6/2/2017andnumbered2017/9901,hasbeenrepealed. PROVISIONALARTICLE1-(1)Thevalueof1EuroinTurkishLiratobeusedinthepricingof medicinalproductsforhumanusehasbeendeterminedasTL26.8767,withthe65%ratespecifiedinthe thirdparagraphofArticle2tobe60%until1/4/2026.

sion published by the Turkish Medicines and Medical Devices Agency (TİTCK), imported from the AIFD Legislation Portal archive. In the event of any discrepancy, the Turkish original text (mevzuat.g

(2)Thevaluesof80%,75%and70%inthetenthparagraphofArticle2shallapplytothefirst equivalentproductsplacedonthemarketaftertheeffectivedateofthisDecreeandtootheridenticaland comparableproductsofthesefirstequivalentproducts;theyshallnotapplytoproductscurrentlypricedat 60%.Forproductsalreadyauthorizedbutplacedonthemarketaftertheentryintoforceofthis Decree,the effectivedateofthisDecreeshallbeusedinthecalculationofthedateofauthorization.
(3)Theeffectivedateofthepricescalculatedaccordingto January 1,2000,asstatedintheeighth paragraphofArticle2,istheeffectivedateannouncedattheendofthe2026sourcepricechangeperiod. Untilthiseffectivedate,Pricescalculatedaccordingtothedateof August 1,1987,asstatedinthefourth paragraphofArticle2oftheDecreeonthePricingofHumanMedicinalProducts,whichwasrepealedby Article9,shallcontinuetoapply.Duringthe2026sourcepricechangeperiod,thefirstpriceapplications shallbesubmittedandevaluatedinaccordancewiththeprovisionsoftheeighthparagraphofArticle2of thisDecreeandtherelevantprovisionsofthefourthparagraphofArticle2oftheDecreeonthePricingof HumanMedicinalProducts,whichisrepealedbyArticle9.
(4)ThefourteenthparagraphofArticle2oftheDecreeonthePricingofHumanMedicinal Products,whichwasrepealedbyArticle9,shallremaininforceuntiltheeffectivedateannouncedatthe endofthe2026sourcepricechangeperiod.However,theprovisionsofthisDecreeshallbetakenasabasis i ntheassessmentstobemadeduringthe2026actualsourcepricechangeperiod.Thepricesdeterminedby theprovisionsofthisDecreeshallbevalidontheeffectivedateannouncedattheendofthe2026actual sourcepricechangeperiod.
PROVISIONALARTICLE2-(1)TheprovisionsoftheCommuniquéonthePricingofMedicinal ProductsforHumanUseissuedpursuanttotheDecreeonthePricingofMedicinalProductsforHuman UseputintoeffectbytheCouncilofMinistersDecisiondated6/2/2017andnumbered2017/9901,which donotconflictwiththisDecree,shallapplyuntilanewcommuniquéisissuedpursuanttothisDecree.
PROVISIONALARTICLE3-(1)Thevalueof1EuroinTurkishLiratobeusedinthepricingof humanmedicinalproductshasbeensetatTRY29.1164,effectiveasofApril1,2026,attherateof65% specifiedinthethirdparagraphofArticle2.
(2)Effectivefrom1/4/2026,thethresholdsinArticle2shallbeappliedasTRY100.37for price-protectedproductsandTRY52.44forotherproducts.
(3)Effectivefrom1/4/2026,thevalueinthetenthparagraphofArticle2shallbeappliedasTRY 151.25.
(4)Effectivefrom1/4/2026,thethresholdsinthefirstparagraphofArticle6shallbeappliedas TRY440.65andTRY882.66.
PROVISIONALARTICLE4-(1)ThethirdparagraphofArticle3shallnotapplytothefirst paragraphofprovisionalArticle1andprovisionalArticle3. Effectiveness ARTICLE10-(1)ThisDecreeshallbecomeeffectiveonthedayfollowingthedateofitsissuance. Enforcement ARTICLE11-TheprovisionsofthisDecreeshallbeexecutedbythePresident.

sion published by the Turkish Medicines and Medical Devices Agency (TİTCK), imported from the AIFD Legislation Portal archive. In the event of any discrepancy, the Turkish original text (mevzuat.g